Showing results 2 to 4 of 4
< previous
Title | Author(s) | Issue Date | |
---|---|---|---|
Polyuria due to vasopressin V2 receptor antagonism is not associated with increased ureter diameter in ADPKD patients Journal:Clinical and Experimental Nephrology | 2017 | ||
Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3-4 study Journal:American Journal of Kidney Diseases | 2011 | ||
Tolvaptan in autosomal dominant polycystic kidney disease: Three years' experience Journal:Clinical Journal of the American Society of Nephrology | 2011 |